Arbutus Biopharma downgraded to Neutral from Buy at B. Riley FBR. B. Riley FBR analyst Madhu Kumar downgraded Arbutus Biopharma to Neutral with an unchanged price target of $9. The analyst cites valuation for the downgrade following the stock’s recent rally.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.